Home Tags Cancer: Prostate

Tag: Cancer: Prostate

Prostate cancer clinical trial participants are overwhelmingly white

Prostate Cancer Trial Participants Overwhelmingly White

Since 1990, proportion of white participants in prostate cancer clinical trials has remained >80 percent
For men with advanced prostate cancer

ASCO: Relugolix Superior to Leuprolide in Advanced Prostate Cancer

And, enzalutamide improves median overall survival in nonmetastatic, castration-resistant prostate cancer
Prostate cancer incidence rates decreased from 2005 to 2016 for local-stage disease among men aged ≥50 years but increased for regional- and distant-stage disease

Local-Stage Prostate Cancer Incidence Rates Continue to Drop

Rates of regional- and distant-stage prostate cancer increasing in the U.S. among men aged ≥50 years
Among prostate cancer patients

Risk for SARS-CoV-2 Lower for Prostate Cancer Patients on ADT

Risk reduced fourfold with androgen-deprivation therapy versus other treatment for prostate cancer
Genomic targeted prostate cancer treatment shows a survival benefit in patients with metastatic castration-resistant prostate cancer

Genomically Targeted Treatment Slows Advanced Prostate Cancer

Men receiving olaparib versus standard treatment experience delayed disease progression
National

Racial Disparity in Prostate Cancer Survival Tied to Region

Mortality risk for low-risk prostate cancer more than fivefold higher for black versus white men in Atlanta
In a special article published online April 1 in Advances in Radiation Oncology

Radiotherapy for Prostate Cancer Adjusted During COVID-19

Telemedicine consults recommended; treatment can be avoided, delayed in low, intermediate-risk disease
For men with intermediate- and high-risk prostate adenocarcinoma

10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer

10-year cumulative incidence of biochemical and/or clinical disease failure no different with C-, H-IMRT
Combined biopsy

Combined Biopsy Method Better for Prostate Cancer Diagnosis

Cancer diagnosed in 9.9 percent more, upgrading seen in 21.8 percent with MRI-targeted + systematic biopsy
Surgical approach is not associated with intermediate-term decision regret following radical prostatectomy

Surgical Approach Not Tied to Decision Regret After Prostatectomy

Functional and oncologic outcomes, autonomous decision-making, and follow-up time influence regret